Anavex Life Sciences Corp.

10/31/2024 | Press release | Distributed by Public on 10/31/2024 08:03

Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation